(E,Z)-7-phenyl-7-(pyridin-3-yl)-6-heptenoic acid | 89667-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E,Z)-7-phenyl-7-(pyridin-3-yl)-6-heptenoic acid
• 英文别名: CV 4193；(Z)-7-phenyl-7-(pyridin-3-yl)-hept-6-enoic acid；(Z)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid；7-phenyl-7-(pyridin-3-yl)-6-heptenic acid；isbogrel；+(Z)-7-(pyridin-3-yl)-7-phenyl-6-heptenoic acid；(Z)-7-phenyl-7-pyridin-3-ylhept-6-enoic acid
• CAS: 89667-39-0
• 化学式: C₁₈H₁₉NO₂
• 分子量: 281.354
• InChiKey: UWPBQLKEHGGKKD-BOPFTXTBSA-N

物化性质

• 熔点：
  108-110 °C
• 沸点：
  481.7±34.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E,Z)-7-phenyl-7-(pyridin-3-yl)-6-heptenoic acid 生成 伊波格雷
  参考文献：
  名称：

  TERAO, SHINJI;NISHIKAWA, KOHEI

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氧代己酸甲酯 在 四(三苯基膦)钯 、 水 、 magnesium 、 三苯基膦 、 lithium chloride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 21.58h， 生成 (E,Z)-7-phenyl-7-(pyridin-3-yl)-6-heptenoic acid
  参考文献：
  名称：

  使用 Pd 催化从烯烃模板合成立体定义的三取代烯烃 - 抗高血压 Isbogrel 的合成

  摘要：

  已经开发了一系列高度官能化的三取代烯烃结构单元（模板），用于将它们在 Pd 催化下加工成更复杂的结构，包括天然产物和具有药物化学意义的化合物。Pd 介导的转化涉及烯丙基取代和交叉偶联反应的组合。模板的设计使得这些过程不仅具有高度的区域选择性和立体选择性，而且可以使用相同的催化剂在同一个烧瓶中依次进行转化。

  DOI：

  10.1002/ejoc.201100849

文献信息

• 7-phenyl-7-(3-pyridyl)-6-heptenoic acid or derivatives thereof which
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04727078A1

  公开（公告）日：1988-02-23

  Novel compound of the formula: ##STR1## wherein R.sup.1 is pyridyl group, R.sup.2 is a phenyl group, a thienyl group, a furyl group, a naphthyl group, a benzothienyl group or pyridyl group, which may optionally have a lower alkoxy group, a lower alkyl group, a halogen atom, trifluoromethyl group, a lower alkenyl group or methylenedioxy group, R.sup.3 is hydrogen atom or a lower alkyl group, and n is an integer of 0 to 6, Y is sulphur atom, methylene group or a group of the formula: ##STR2## wherein R.sup.4 is hydrogen atom or acetyl group, and m is 0 or 1, and their pharmaceutically acceptable salts have an inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of accelerating the productivility of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to the prophylaxis or therapy of thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

  化合物的新型配方：##STR1## 其中，R.sup.1是吡啶基，R.sup.2是苯基，噻吩基，呋喃基，萘基，苯并噻吩基或吡啶基，可选地带有较低的烷氧基，较低的烷基，卤素原子，三氟甲基基团，较低的烯基或亚甲二氧基基团，R.sup.3是氢原子或较低的烷基，n是0到6的整数，Y是硫原子，亚甲基基团或公式的基团：##STR2## 其中，R.sup.4是氢原子或乙酰基，m是0或1，它们的药学上可接受的盐具有抑制血栓素A.sub.2（TXA.sub.2）的生物合成作用和加速前列腺素I.sub.2（PGI.sub.2）的产生能力，可用于哺乳动物的预防或治疗由血小板聚集引起的血栓形成或由心脏，脑和周围循环系统的血管痉挛引起的缺血性疾病（例如心肌梗塞，中风，肾脏，肺和其他器官的血管梗塞，消化性溃疡等）。
• Certain pyridyl alkenoic acid derivatives which inhibit the action of
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04760068A1

  公开（公告）日：1988-07-26

  Novel compound of the formula: ##STR1## wherein R.sup.1 is pyridyl group, R.sup.2 is a phenyl group, a thienyl group, a furyl group, a naphthyl group, a benzothienyl group or pyridyl group, which may optionally have a lower alkoxy group, a lower alkyl group, a halogen atom, trifluoromethyl group, a lower alkenyl group or methylenedioxy group, R.sup.3 is hydrogen atom or a lower alkyl group, and n is an integer of 0 to 6, Y is sulphur atom, methylene group or a group of the formula: ##STR2## wherein R.sup.4 is hydrogen atom or acetyl group, and m is 0 or 1, and their pharmaceutically acceptable salts having an inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of accelerating the productivility of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to the prophylaxis or therapy of thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

  化合物的结构式为：##STR1## 其中R.sup.1是吡啶基，R.sup.2是苯基、噻吩基、呋喃基、萘基、苯并噻吩基或吡啶基，可以选择性地具有较低的烷氧基、较低的烷基、卤素原子、三氟甲基基团、较低的烯基或亚甲氧基基团，R.sup.3是氢原子或较低的烷基，n为0到6的整数，Y是硫原子、亚甲基基团或式子：##STR2## 其中R.sup.4是氢原子或乙酰基团，m为0或1，以及其药学上可接受的盐，具有抑制血栓素A.sub.2（TXA.sub.2）的生物合成和加速前列腺素I.sub.2（PGI.sub.2）的产生的作用，并可用于哺乳动物的预防或治疗由血小板聚集引起的血栓形成或由心脏、脑和周围循环系统中的血管痉挛引起的缺血性疾病（例如心肌梗塞、中风、肾脏、肺和其他器官的血管梗塞、消化性溃疡等）。
• Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04563446A1

  公开（公告）日：1986-01-07

  Novel compounds of the formula: ##STR1## wherein R.sup.2 is an aromatic or heterocyclic group, which may optionally be substituted, R.sup.2 is a methyl group, a hydroxymethyl group, a nitroxymethyl group, a formyl group, a nitrogen-containing five-membered ring-methyl group, an acetal-methyl group, a trialkylsilyloxymethyl group, an alkyl- or aryl-sulfonyloxymethyl group, an alkyl- or aryl-sulfonylaminocarbonyloxymethyl group, an acyloxymethyl group, an alkoxycarbonyloxymethyl group, a halogenomethyl group, an alkoxymethyl group, an aryloxymethyl group, a cyano group, a carbamoyl group which may optionally be substituted, a carbamoyloxymethyl group which may optionally be substituted, a thiocarbamoyloxymethyl group which may optionally be substituted, and an alkoxycarbonyl group, n is an integer of 1 to 20, and ##STR2## provided that n is an integer of 9 to 20 when ##STR3## and, at the same time, R.sup.2 is a carboxyl group or an alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, have a selective inhibitory action on biosynthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of enhancing the production of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to prevent and treat arterial thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, stroke, occlusion of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

  该化合物的新型化合物的公式为：##STR1## 其中R.sup.2是芳香或杂环基团，可以选择性地被取代，R.sup.2是甲基基团、羟甲基基团、硝基甲基基团、甲酰基基团、含氮五元环甲基基团、缩醛基甲基基团、三烷基硅氧基甲基基团、烷基或芳基磺酰氧基甲基基团、烷基或芳基磺酰氨基羰氧基甲基基团、酰氧基甲基基团、烷氧羰氧基甲基基团、卤代甲基基团、烷氧基甲基基团、芳氧基甲基基团、氰基、可以选择性地被取代的氨基甲酰基、可以选择性地被取代的氨基甲酰氧基、可以选择性地被取代的硫脲甲酰氧基和烷氧羰基基团，n是1到20的整数，且当##STR3## 同时，R.sup.2是羧基或烷氧羰基基团时，n是9到20的整数，或其药学上可接受的盐，具有选择性抑制血栓素A.sub.2(TXA.sub.2)生物合成和增强前列腺素I.sub.2(PGI.sub.2)生产的作用，可用于哺乳动物预防和治疗由血小板聚集引起的动脉血栓形成或由心脏、脑和周围循环系统(如心肌梗塞、中风、肾脏、肺和其他器官的血管闭塞、胃溃疡等)的血管痉挛引起的缺血性疾病。
• Process for producing substituted vinyl pyridines
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0337640A1

  公开（公告）日：1989-10-18

  An improved process for producing a substituted vinyl pyridine compound of the general formula: wherein R¹ is pyridyl group; R² is an optionally substituted aromatic or heterocyclic group; R³ is a lower alkyl group, hydroxymethyl group, nitroxymethyl group, a nitrogen containing 5 membered ring-methyl group, an acetal-methyl group, a trialkylsilyloxymethyl group, an alkyl- or aryl­sulfonyloxymethyl group, an alkyl- or aryl-sulfonylamino­carbonyloxymethyl group, an acyloxymethyl group, an alkoxycarbonyloxymethyl group, a halogenomethyl group, an alkoxymethyl group, an aryl-oxymethyl group, cyano group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxymethyl group, an optionally substituted thiocarbamoyloxymethyl group, carboxyl group or an alkoxycarbonyl group; and n is an integer of 1 to 22, which comprises reacting a compound of the general formula: wherein R¹ and R² are as defined above, with a compound of the general formula: (C₆H₅)₃P⁺-CH₂CH₂R³·X⁻ wherein R³ is as defined above and X is a halogen atom, in a tertiary alcohol in the presence of a metallic hydride or a tertiary alkoxide of an alkali metal.

  一种生产通式为取代乙烯基吡啶化合物的改进工艺： 其中R¹是吡啶基；R²是任选取代的芳香族或杂环基团；R³是低级烷基、羟甲基、硝基、含氮五元环甲基、缩醛甲基、三烷基硅氧基甲基、烷基或芳基磺酰氧基甲基、烷基或芳基磺酰氨基羰基氧基甲基、酰氧基甲基、卤代甲基、烷氧基甲基、芳基氧基甲基、氰基、任选取代的氨基甲酰基、任选取代的氨基甲酰氧基甲基、任选取代的硫代氨基甲酰氧基甲基、羧基或烷氧基羰基；和 n 是 1 至 22 的整数，其中包括使通式如下的化合物发生反应： 其中 R¹ 和 R² 如上定义，与通式化合物反应： (c₆h₅)₃p⁺-ch₂ch₂r³-x- 其中 R³ 如上定义，X 为卤素原子。
• N-HYDROXYUREA DERIVATIVES
  申请人：Nikken Chemicals Company, Limited

  公开号：EP0807626A1

  公开（公告）日：1997-11-19

  An N-hydroxyurea derivative or a pharmacologically acceptable salt thereof having the formula (I): wherein, A represents CH, CH-CH2, CH-O, or C=CH, X represents O or S, B represents a C1 to C8 alkylene, C2 to C6 alkenylene, m-phenylene, or p-phenylene, R represents a hydrogen atom, halogen atom, C1 to C4 alkyl which may be substituted with a halogen atom, C1 to C4 alkoxy which may be substituted with a halogen atom, or nitro, R1 represents a hydrogen atom, C1 to C4 lower alkyl, or phenyl, and R2 represents a hydrogen atom, C1 to C4 alkyl, cycloalkyl, phenyl which may be substituted with a substituent, or methanesulfonyl.

  一种具有式(I)的 N-羟基脲衍生物或其药理学上可接受的盐： 其中，A 代表 CH、CH-CH2、CH-O 或 C=CH，X 代表 O 或 S，B 代表 C1 至 C8 亚烷基、C2 至 C6 烯基、间苯二酚或对苯二酚，R 代表氢原子、卤素原子、可被卤素原子取代的 C1 至 C4 烷基、可被卤素原子取代的 C1 至 C4 烷氧基或硝基，R1 代表氢原子、卤素原子、可被卤素原子取代的 C1 至 C4 烷氧基或硝基、R1 代表氢原子、C1-C4 低级烷基或苯基，R2 代表氢原子、C1-C4 烷基、环烷基、可被取代基取代的苯基或甲磺酰基。